(antimuscarinics)

amantadine . apomorphine . bromocriptine . cabergoline . pergolide . pramipexole . quinagolide .ropinirole .rotigotine.

FOOD AND LIFESTYLE Dose adjustment might be necessary if

smoking started or stopped during treatment with ropinirole.

▶ Amisulpride is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 9

p. 1377

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to bromocriptine.rTheoretical

▶ Antiarrhythmics (dronedarone) are predicted to increase the

concentration of cabergoline.rAnecdotal

▶ Antifungals, azoles (fluconazole, isavuconazole, itraconazole,

ketoconazole, posaconazole, voriconazole) are predicted to

increase the concentration of cabergoline.oAnecdotal

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to

r

bromocriptine.

Theoretical

▶ Antifungals, azoles (isavuconazole) are predicted to increase the

exposure to pramipexole. Adjust dose.oStudy

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole)

increase the exposure to bromocriptine.rStudy

▶ Aprepitant is predicted to increase the exposure to

bromocriptine.rTheoretical

▶ Aprepitant is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Aripiprazole is predicted to decrease the effects of dopamine

receptor agonists.oTheoretical → Also see TABLE 8 p. 1376

▶ Asenapine is predicted to decrease the effects of dopamine

receptor agonists. Adjust dose.oTheoretical → Also see

TABLE 8 p. 1376

▶ Benperidol is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376

▶ Bupropion increases the risk of side-effects when given with

amantadine.oStudy

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to bromocriptine.rTheoretical →

Also see TABLE 8 p. 1376

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the concentration of

Anecdotal → Also see TABLE 8 p. 1376

cabergoline.o ▶ Clozapine is predicted to decrease the effects of dopamine

receptor agonists.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 10 p. 1377

▶ Cobicistat

Study

increases the exposure to bromocriptine.r

▶ Cobicistat is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Combined hormonal contraceptives are predicted to increase

the exposure to ropinirole. Adjust dose.oStudy

▶ Crizotinib is predicted to increase the exposure to

bromocriptine.rTheoretical

▶ Crizotinib is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Dolutegravir is predicted to increase the exposure to

pramipexole. Adjust dose.oStudy

▶ Domperidone is predicted to decrease the prolactin-lowering

effect of dopamine receptor agonists (bromocriptine,

cabergoline).oTheoretical

▶ Dopamine receptor agonists (cabergoline) are predicted to

increase the risk of ergotism when given with dopamine

receptor agonists (bromocriptine). Avoid.oTheoretical →

Also see TABLE 8 p. 1376

▶ Dopamine receptor agonists (bromocriptine, cabergoline) are

predicted to increase the risk of ergotism when given with

dopamine receptor agonists

Theoretical → Also see TABLE 8

(pergolide)

p. 1376

. Avoid.o ▶ Dopamine receptor agonists (amantadine) are predicted to

increase the exposure to dopamine receptor agonists

(pramipexole). Adjust dose.oTheoretical → Also see

TABLE 8 p. 1376

▶ Droperidol is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

▶ Ergometrine is predicted to increase the risk of ergotism when

given with dopamine receptor agonists (cabergoline, pergolide).

Avoid.oTheoretical

1444 Dolutegravir — Dopamine receptor agonists BNF 78

Interactions | Appendix 1

A1

▶ Ergotamine is predicted to increase the risk of ergotism when

given with dopamine receptor agonists (bromocriptine,

cabergoline). Avoid.oTheoretical

▶ Ergotamine is predicted to increase the risk of ergotism when

given with pergolide.oTheoretical

▶ Flupentixol is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376

▶ Apomorphine is predicted to increase the risk of severe

hypotension when given with granisetron.rTheoretical

▶ H2 receptor antagonists (cimetidine) are predicted to increase

the exposure to pramipexole. Adjust dose.oStudy

▶ Haloperidol is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377 → Also see TABLE 10 p. 1377

▶ HIV-protease inhibitors

r

increase the exposure to bromocriptine.

Study

▶ HIV-protease inhibitors are predicted to increase the

concentration of cabergoline.oAnecdotal

▶ Hormone replacement therapy decreases the clearance of

ropinirole. Monitor and adjust dose.oStudy

▶ Idelalisib increases the exposure to bromocriptine.rStudy

▶ Idelalisib is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Imatinib is predicted to increase the exposure to

bromocriptine.rTheoretical

▶ Imatinib is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Loxapine is predicted to decrease the effects of dopamine

receptor agonists.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 10 p. 1377

▶ Macrolides (clarithromycin) increase the exposure to

bromocriptine.rStudy

▶ Macrolides (clarithromycin, erythromycin) are predicted to

increase the concentration of cabergoline. Avoid.rStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to bromocriptine.rTheoretical

▶ Amantadine increases the risk of CNS toxicity when given with

memantine. Use with caution or avoid.rTheoretical

▶ Memantine is predicted to increase the effects of dopamine

receptor agonists (apomorphine, bromocriptine, cabergoline,

pergolide, pramipexole, quinagolide, ropinirole, rotigotine)

o .

Theoretical

▶ Metoclopramide is predicted to decrease the effects of

dopamine receptor agonists (apomorphine, bromocriptine,

cabergoline, pergolide, pramipexole, quinagolide, ropinirole,

rotigotine). Avoid.oStudy

▶ Mexiletine is predicted to increase the exposure to ropinirole.

Adjust dose.oStudy

▶ Netupitant is predicted to increase the exposure to

bromocriptine.rTheoretical

▶ Netupitant is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Nilotinib is predicted to increase the exposure to

bromocriptine.rTheoretical

▶ Nilotinib is predicted to increase the concentration of

cabergoline.oAnecdotal

▶ Olanzapine is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376

▶ Apomorphine increases the risk of severe hypotension when

given with ondansetron. Avoid.rStudy → Also see TABLE 9

p. 1377

▶ Paliperidone is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

▶ Apomorphine is predicted to increase the risk of severe

hypotension when given with palonosetron.rTheoretical

▶ Phenothiazines are predicted to decrease the effects of

dopamine receptor agonists. Avoid.oTheoretical → Also

see TABLE 8 p. 1376 → Also see TABLE 9 p. 1377 → Also see TABLE 10

p. 1377

▶ Pimozide is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377 → Also see TABLE 10 p. 1377

▶ Quetiapine is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376

▶ Quinolones (ciprofloxacin) are predicted to increase the

exposure to ropinirole. Adjust dose.oStudy

▶ Ranolazine is predicted to increase the exposure to

pramipexole. Adjust dose.oStudy

▶ Risperidone is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

▶ SSRIs (fluvoxamine) are predicted to increase the exposure to

ropinirole. Adjust dose.oStudy

▶ Sulpiride is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

▶ Sympathomimetics, vasoconstrictor (isometheptene) potentially

increase the risk of side-effects when given with

bromocriptine. Avoid.rAnecdotal

▶ Trimethoprim is predicted to increase the exposure to

pramipexole. Adjust dose.oStudy

▶ Vandetanib is predicted to increase the exposure to

pramipexole. Adjust dose.oStudy

▶ Zuclopenthixol is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

Doravirine

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to doravirine. Avoid.rStudy

▶ Antiepileptics (oxcarbazepine) are predicted to decrease the

exposure to doravirine. Avoid.rTheoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to doravirine.nStudy

▶ Bosentan is predicted to decrease the exposure to doravirine.

Avoid or adjust doravirine dose, p. 644.rTheoretical

▶ Cobicistat is predicted to increase the exposure to doravirine.

nStudy

▶ Dabrafenib is predicted to decrease the exposure to doravirine.

Avoid or adjust doravirine dose, p. 644.rTheoretical

▶ Efavirenz is predicted to decrease the exposure to doravirine.

Avoid or adjust doravirine dose, p. 644.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

doravirine. Avoid.rStudy

▶ HIV-protease inhibitors are predicted to increase the exposure

to doravirine.nStudy

▶ Idelalisib is predicted to increase the exposure to doravirine.

nStudy

▶ Lumacaftor is predicted to decrease the exposure to

doravirine. Avoid.rTheoretical

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to doravirine.nStudy

▶ Mitotane is predicted to decrease the exposure to doravirine.

Avoid.rStudy

▶ Modafinil is predicted to decrease the exposure to doravirine.

Avoid or adjust doravirine dose, p. 644.rTheoretical

▶ Nevirapine is predicted to decrease the exposure to doravirine.

Avoid or adjust doravirine dose, p. 644.rTheoretical

▶ Rifabutin moderately decreases the exposure to doravirine.

Adjust doravirine dose, p. 644.rStudy

▶ Rifampicin is predicted to decrease the exposure to doravirine.

Avoid.rStudy

▶ Doravirine is predicted to decrease the exposure to sirolimus.

Monitor

o

sirolimus concentration and adjust dose, p. 840.

Theoretical

▶ St John’s Wort is predicted to decrease the exposure to

doravirine. Avoid.rTheoretical

▶ Doravirine is predicted to decrease the exposure to tacrolimus.

Monitor

o

tacrolimus concentration and adjust dose, p. 841.

Theoretical

▶ Telotristat ethyl is predicted to decrease the exposure to

doravirine

Theoretical

. Avoid or adjust doravirine dose, p. 644.r

BNF 78 Dopamine receptor agonists — Doravirine 1445

Interactions | Appendix 1

A1

Dorzolamide

ROUTE-SPECIFIC INFORMATION Since systemic absorption can

follow topical application, the possibility of interactions

should be borne in mind.

Dosulepin → see tricyclic antidepressants

Doxapram

▶ Aminophylline increases the risk of agitation when given with

doxapram.oStudy

▶ Monoamine-oxidase A and B inhibitors, irreversible are

predicted to increase the effects of

Theoretical

doxapram.o ▶ Theophylline increases the risk of agitation when given with

doxapram.oStudy

Doxazosin → see alpha blockers

Doxepin → see tricyclic antidepressants

Doxorubicin → see anthracyclines

Doxycycline → see tetracyclines

Doxylamine → see antihistamines, sedating

Dronedarone → see antiarrhythmics

Droperidol → see TABLE 8 p. 1376 (hypotension), TABLE 9 p. 1377 (QTinterval prolongation), TABLE 11 p. 1377 (CNS depressant effects)

▶ Droperidol is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

▶ Droperidol is predicted to decrease the effects of guanethidine.

Monitor and adjust dose.oTheoretical → Also see TABLE 8

p. 1376

▶ Droperidol decreases the effects of levodopa.rStudy →

Also see TABLE 8 p. 1376

Drospirenone → see TABLE 16 p. 1379 (increased serum potassium)

▶ Antifungals, azoles (ketoconazole) moderately increase the

exposure to drospirenone.rStudy

Dulaglutide → see TABLE 14 p. 1378 (antidiabetic drugs)

Duloxetine → see TABLE 18 p. 1379 (hyponatraemia), TABLE 13 p. 1378

(serotonin syndrome), TABLE 4 p. 1375 (antiplatelet effects)

▶ Antiepileptics (phenytoin) are predicted to decrease the

exposure to duloxetine.oTheoretical

▶ Duloxetine is predicted to increase the exposure to beta

blockers, selective (metoprolol).oStudy

▶ Duloxetine is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ HIV-protease inhibitors (ritonavir) are predicted to decrease the

exposure to duloxetine.oTheoretical

▶ Leflunomide is predicted to decrease the exposure to

duloxetine.oTheoretical

▶ Duloxetine is predicted to increase the exposure to pitolisant.

Use with caution and adjust dose.oStudy

▶ Quinolones (ciprofloxacin) are predicted to increase the

exposure to duloxetine. Avoid.oTheoretical

▶ Rifampicin

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more